US President Trump says today as his direction, Dr Mehmet Oz announced that Medicaid will no longer fund gender transition surgeries and hormones for minors

Full post "Today, at my direction, Dr. Mehemet Oz announced that Medicaid will NO LONGER fund gender transition surgeries and hormones for minors. We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies. Thanks to our strong position and pressure on this issue over the past year and a half, dozens of U.S. hospitals have already ended this so-called “gender-affirming care,” and we expect many more to follow. Just think about all of the young, innocent, and perhaps confused children who will be spared! While the Dumocrat Party wants your kids to be able to chop off their reproductive organs before they are old enough to vote, President Donald J. Trump (ME!) and the Republican Party say that is ABSURD, and we will protect America’s children. Please remember this when you are casting your vote in the Midterm Elections in November. Thank you for your attention to this very important matter! President DONALD J. TRUMP"

Federal moves to restrict Medicaid funding for specific categories of care have historically been delivered through agency rulemaking or coverage determinations rather than announcements of this kind, and the gap between the two matters: formal rules carry notice-and-comment periods and have typically drawn immediate legal challenge from states, providers, and affected groups, with courts frequently enjoining implementation pending review. Past episodes of healthcare coverage restrictions announced politically have followed a sequence of agency action, injunction, and protracted litigation, so the operative question is the mechanism cited and whether a published rule or guidance follows. For markets the transmission channel is narrow and name-specific rather than macro: hospital systems and pediatric providers with exposure to this service line, and managed care organisations administering Medicaid plans, bear the direct read-through, though for most operators this is a negligible share of revenue and prior restrictions of this type have not moved the broader healthcare complex. The reference to hospitals already ending such programmes indicates the policy has been operating through pressure and state-level action ahead of any federal funding step, which limits incremental repricing. Worth watching is the formal CMS instrument, if any, and the litigation response that has reliably attended comparable federal health coverage directives.